<DOC>
	<DOCNO>NCT00374881</DOCNO>
	<brief_summary>Efficacy Safety combine oral adjuvant phenylephrine sorbitol oral low dose morphine analgesia .</brief_summary>
	<brief_title>A Study Safety Efficacy Combination Therapy With Morphine , Phenylephrine Sorbitol Human Subjects</brief_title>
	<detailed_description>The primary objective study determine efficacy combine oral adjuvant phenylephrine sorbitol oral low dose morphine analgesia .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Sorbitol</mesh_term>
	<criteria>Ability provide write informed consent Healthy male female 18 40 year age , inclusive . Women test negative pregnancy . Body weight within 15 % ideal body weight base Metropolitan Life assurance table . No concomitant medication ( prescription , OTC , vitamin , dietary supplement ) within 7 day prior administration study medication study period . Ability adhere visit schedule protocol requirement available complete study Ability participate successfully train session arrange volunteer prior study day , acquire consistency test perform . Ability satisfy medical examiner fitness participate study prior use chronic opioids mental illness prior present evidence significant concomitant disease , include renal , hepatic , cardiovascular , pulmonary , endocrinological , hematopoietic , gastrointestinal disease , neoplasm clinically significant medical disorder , Investigator 's judgment contraindicate administration study medication know allergy drug use study history drug alcohol abuse significant abnormality screen physical exam administration drug may potentially inhibit induce liver cytochrome P450 activity within 3 week prior Day 0 acute medical situation ( e.g . acute infection ) within 48 hour Day 0 , consider significance Principal Investigator unusual diet administration experimental medication within previous 12 week . inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) subject , judgment investigator , likely noncompliant uncooperative unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>